Kotoula, Vassiliki

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 2,144

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

Pentheroudakis, G., Kotoula, V., De Roock, W., Kouvatseas, G., Papakostas, P., Makatsoris, T., Papamichael, D., Xanthakis, I., Sgouros, J., Televantou, D., et al. (2013) · BMC Cancer

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 111

The Prognostic Role of Ephrin A2 and Endothelial Growth Factor Receptor Pathway Mediators in Patients With Advanced Colorectal Cancer Treated With Cetuximab

Strimpakos, A., Pentheroudakis, G., Kotoula, V., De Roock, W., Kouvatseas, G., Papakostas, P., Makatsoris, T., Papamichael, D., Andreadou, A., Sgouros, J., et al. (2013) · Clinical Colorectal Cancer

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 27